Sanofi looks east with €300m Innovent cancer alliance
Sanofi is making a €300 million investment in Chinese biotech Innovent as part of a collaboration to bring two new cancer therapies as quickly as […]
Sanofi is making a €300 million investment in Chinese biotech Innovent as part of a collaboration to bring two new cancer therapies as quickly as […]
FDA advisors have voted against approval of Eli Lilly and Innovent Biologics’ cancer immunotherapy sintilimab, undermining hopes of a new, lower-priced option in the PD-1/PD-L1 […]
The FDA has dropped a bomb on Eli Lilly’s marketing application for cancer immunotherapy sintilimab ahead of an advisory committee meeting due to take place […]
Shots: The companies collaborated to evaluate the safety, PK, PD & preliminary efficacy of the combination therapy of Innovent’s sintilimab + NeoCura’s NEO_PLIN2101 in patients […]
Eli Lilly made a late entry into the checkpoint inhibitor market when it licensed ex-China rights to Innovent’s sintilimab last year, and a new trial […]
Shots: The P-III ORIENT-31 study evaluates sintilimab with/out Byvasda + CT vs CT in a ratio (1:1:1) in patients with EGFR-mutated LA or metastatic nonsq. […]
Shots: The P-III ORIENT-11 study evaluates the efficacy & safety of sintilimab (200mg) + pemetrexed and platinum CT vs PBO + CT in 397 patients […]
The FDA has accepted Eli Lilly and China’s Innovent filing for their latecomer immunotherapy sintilimab, which is expected to compete on price with rivals such […]
Shots: The submission is based on a P-III ORIENT-11 study assessing sintilimab (200mg) + pemetrexed and platinum CT vs PBO + CT as a 1L […]
Shots: The P-III ORIENT-3 trial involves assessing the efficacy and safety of Tyvyt (sintilimab) vs docetaxel (q3w) in 290 patients in a ratio (1:1) as […]
Shots: The 7 studies include one Proffered Paper Oral Presentation & 6 e-posters, covering indications including lung cancer, liver cancer, gastric cancer, & esophageal cancer […]
Shots: Innovent to receive $200M up front, $825M as development and commercial milestones along with royalties on net sales of the therapy. Both the companies […]
Shots: The NMPA has accepted the sNDA for Tyvyt (sintilimab) in combination with Gemzar (gemcitabine) and platinum as 1L therapy in sq. NSCLC The sNDA […]
Copyright © 2024 | WordPress Theme by MH Themes